{"id":"https://openalex.org/W4415523640","doi":"https://doi.org/10.1158/2767-9764.crc-25-0243","title":"A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies","display_name":"A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies","publication_year":2025,"publication_date":"2025-10-24","ids":{"openalex":"https://openalex.org/W4415523640","doi":"https://doi.org/10.1158/2767-9764.crc-25-0243","pmid":"https://pubmed.ncbi.nlm.nih.gov/41134690"},"language":"en","primary_location":{"id":"doi:10.1158/2767-9764.crc-25-0243","doi":"https://doi.org/10.1158/2767-9764.crc-25-0243","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-25-0243","pdf_url":"https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-25-0243/3665428/crc-25-0243.pdf","source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-25-0243/3665428/crc-25-0243.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087308492","display_name":"Dejan Juric","orcid":"https://orcid.org/0000-0003-2983-7704","observed_orcids":["https://orcid.org/0000-0003-2983-7704"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dejan Juric","raw_affiliation_strings":["1Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, Massachusetts","Massachusetts General Hospital Cancer Center, Boston, MA, United States"],"raw_orcid":"https://orcid.org/0000-0003-2983-7704","affiliations":[{"raw_affiliation_string":"1Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA, United States","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066873406","display_name":"Daniel M. Anderson","orcid":"https://orcid.org/0009-0000-7229-4085","observed_orcids":["https://orcid.org/0009-0000-7229-4085"]},"institutions":[{"id":"https://openalex.org/I4210120135","display_name":"Metro-Minnesota Community Oncology Research Consortium","ror":"https://ror.org/02vhx9606","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210120135"]},{"id":"https://openalex.org/I52792670","display_name":"HealthPartners","ror":"https://ror.org/03s9ada67","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I52792670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Anderson","raw_affiliation_strings":["2HealthPartners Oncology, HealthPartners Institute, Minneapolis, Minnesota","Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, United States"],"raw_orcid":"https://orcid.org/0009-0000-7229-4085","affiliations":[{"raw_affiliation_string":"2HealthPartners Oncology, HealthPartners Institute, Minneapolis, Minnesota","institution_ids":["https://openalex.org/I52792670"]},{"raw_affiliation_string":"Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, United States","institution_ids":["https://openalex.org/I4210120135"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036587861","display_name":"Afshin Dowlati","orcid":"https://orcid.org/0000-0003-4535-6839","observed_orcids":["https://orcid.org/0000-0003-4535-6839"]},"institutions":[{"id":"https://openalex.org/I4210119077","display_name":"University Hospitals Seidman Cancer Center","ror":"https://ror.org/02kb97560","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972","https://openalex.org/I4210119077"]},{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Afshin Dowlati","raw_affiliation_strings":["3Department of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio","University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, United States"],"raw_orcid":"https://orcid.org/0000-0003-4535-6839","affiliations":[{"raw_affiliation_string":"3Department of Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio","institution_ids":["https://openalex.org/I4210119077","https://openalex.org/I58956616"]},{"raw_affiliation_string":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, United States","institution_ids":["https://openalex.org/I4210119077","https://openalex.org/I58956616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031165814","display_name":"Jordi A. Rodon","orcid":"https://orcid.org/0000-0001-6467-3632","observed_orcids":["https://orcid.org/0000-0001-6467-3632"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordi Rodon","raw_affiliation_strings":["4Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas","The University of Texas MD Anderson Cancer Center, Houston, Texas, United States"],"raw_orcid":"https://orcid.org/0000-0001-6467-3632","affiliations":[{"raw_affiliation_string":"4Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, Texas, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041689810","display_name":"Iwona A. Lugowska","orcid":"https://orcid.org/0000-0001-9511-178X","observed_orcids":["https://orcid.org/0000-0001-9511-178X"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Iwona Lugowska","raw_affiliation_strings":["5Centre for Excellence in Precision Oncology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland","Maria Sk\u0142odowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland"],"raw_orcid":"https://orcid.org/0000-0001-9511-178X","affiliations":[{"raw_affiliation_string":"5Centre for Excellence in Precision Oncology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland","institution_ids":["https://openalex.org/I4210150880"]},{"raw_affiliation_string":"Maria Sk\u0142odowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050913534","display_name":"S\u0142awomir Ma\u0144dziuk","orcid":"https://orcid.org/0000-0002-9812-0777","observed_orcids":["https://orcid.org/0000-0002-9812-0777"]},"institutions":[{"id":"https://openalex.org/I121032520","display_name":"Medical University of Lublin","ror":"https://ror.org/016f61126","country_code":"PL","type":"education","lineage":["https://openalex.org/I121032520"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"S\u0142awomir Ma\u0144dziuk","raw_affiliation_strings":["6Medical University of Lublin, Lublin, Poland","Medical University of Lublin, Lublin, Poland"],"raw_orcid":"https://orcid.org/0000-0002-9812-0777","affiliations":[{"raw_affiliation_string":"6Medical University of Lublin, Lublin, Poland","institution_ids":["https://openalex.org/I121032520"]},{"raw_affiliation_string":"Medical University of Lublin, Lublin, Poland","institution_ids":["https://openalex.org/I121032520"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066795023","display_name":"Yuqin Song","orcid":"https://orcid.org/0000-0003-3067-5554","observed_orcids":["https://orcid.org/0000-0003-3067-5554"]},"institutions":[{"id":"https://openalex.org/I4210093964","display_name":"Peking University Cancer Hospital","ror":"https://ror.org/00nyxxr91","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093964"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yuqin Song","raw_affiliation_strings":["7Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China"],"raw_orcid":"https://orcid.org/0000-0003-3067-5554","affiliations":[{"raw_affiliation_string":"7Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China","institution_ids":["https://openalex.org/I4210093964"]},{"raw_affiliation_string":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China","institution_ids":["https://openalex.org/I4210093964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073166528","display_name":"Feng Jung Sherida H. Woei-A-Jin","orcid":"https://orcid.org/0000-0001-7840-6156","observed_orcids":["https://orcid.org/0000-0001-7840-6156"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Feng Jung Sherida H. Woei-A-Jin","raw_affiliation_strings":["8Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium","University Hospital Leuven, Belgium"],"raw_orcid":"https://orcid.org/0000-0001-7840-6156","affiliations":[{"raw_affiliation_string":"8Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]},{"raw_affiliation_string":"University Hospital Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077504536","display_name":"Marc P.E. Andr\u00e9","orcid":"https://orcid.org/0000-0001-7101-810X","observed_orcids":["https://orcid.org/0000-0001-7101-810X"]},"institutions":[{"id":"https://openalex.org/I4210093617","display_name":"CHU Dinant Godinne UCL Namur","ror":"https://ror.org/00ntbvq76","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4210093617"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Marc Andr\u00e9","raw_affiliation_strings":["9Hematology Department, CHU UCL Namur, Yvoir, Belgium","CHU UCL Namur, Namur, Belgium"],"raw_orcid":"https://orcid.org/0000-0001-7101-810X","affiliations":[{"raw_affiliation_string":"9Hematology Department, CHU UCL Namur, Yvoir, Belgium","institution_ids":["https://openalex.org/I4210093617"]},{"raw_affiliation_string":"CHU UCL Namur, Namur, Belgium","institution_ids":["https://openalex.org/I4210093617"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064484491","display_name":"Joanna G\u00f3ra\u2010Tybor","orcid":"https://orcid.org/0000-0002-6427-4532","observed_orcids":["https://orcid.org/0000-0002-6427-4532"]},"institutions":[{"id":"https://openalex.org/I4210090876","display_name":"Instytut Hematologii i Transfuzjologi","ror":"https://ror.org/00csw7971","country_code":"PL","type":"facility","lineage":["https://openalex.org/I4210090876"]},{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Joanna G\u00f3ra Tybor","raw_affiliation_strings":["10Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland","Medical University in \u0141\u00f3d\u017a, Hematology Department, Warsaw, Poland"],"raw_orcid":"https://orcid.org/0000-0002-6427-4532","affiliations":[{"raw_affiliation_string":"10Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland","institution_ids":["https://openalex.org/I4210090876"]},{"raw_affiliation_string":"Medical University in \u0141\u00f3d\u017a, Hematology Department, Warsaw, Poland","institution_ids":["https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041612097","display_name":"Jos\u00e9\u2010\u00c1ngel Hern\u00e1ndez\u2010Rivas","orcid":"https://orcid.org/0000-0003-4550-757X","observed_orcids":["https://orcid.org/0000-0003-4550-757X"]},"institutions":[{"id":"https://openalex.org/I121748325","display_name":"Universidad Complutense de Madrid","ror":"https://ror.org/02p0gd045","country_code":"ES","type":"education","lineage":["https://openalex.org/I121748325"]},{"id":"https://openalex.org/I4210165557","display_name":"Hospital Universitario Infanta Leonor","ror":"https://ror.org/05nfzf209","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210165557"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jos\u00e9-\u00c1ngel Hern\u00e1ndez-Rivas","raw_affiliation_strings":["11Hematology Department, Infanta Leonor University Hospital, Complutense University, Madrid, Spain","Servicio de Hematolog\u00eda Hospital Universitario Infanta Leonor. Universidad Complutense, Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0003-4550-757X","affiliations":[{"raw_affiliation_string":"11Hematology Department, Infanta Leonor University Hospital, Complutense University, Madrid, Spain","institution_ids":["https://openalex.org/I121748325","https://openalex.org/I4210165557"]},{"raw_affiliation_string":"Servicio de Hematolog\u00eda Hospital Universitario Infanta Leonor. Universidad Complutense, Madrid, Spain","institution_ids":["https://openalex.org/I4210165557"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I204308271","display_name":"Medical College of Wisconsin","ror":"https://ror.org/00qqv6244","country_code":"US","type":"education","lineage":["https://openalex.org/I204308271"]},{"id":"https://openalex.org/I4391012559","display_name":"WIN Consortium","ror":"https://ror.org/03r6bpj37","country_code":null,"type":"nonprofit","lineage":["https://openalex.org/I4391012559"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["12WIN Consortium for Precision Medicine, Chevilly-Larue, France","13Medical College of Wisconsin, Milwaukee, Wisconsin","Worldwide Innovative Network (WIN) for Personalized Cancer Therapy, Villejuif, France"],"raw_orcid":"https://orcid.org/0000-0003-4110-1214","affiliations":[{"raw_affiliation_string":"12WIN Consortium for Precision Medicine, Chevilly-Larue, France","institution_ids":["https://openalex.org/I4391012559"]},{"raw_affiliation_string":"13Medical College of Wisconsin, Milwaukee, Wisconsin","institution_ids":["https://openalex.org/I204308271"]},{"raw_affiliation_string":"Worldwide Innovative Network (WIN) for Personalized Cancer Therapy, Villejuif, France","institution_ids":["https://openalex.org/I4391012559"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010733763","display_name":"Armando L\u00f3pez\u2010Guillermo","orcid":"https://orcid.org/0000-0002-8588-8381","observed_orcids":["https://orcid.org/0000-0002-8588-8381"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Armando L\u00f3pez-Guillermo","raw_affiliation_strings":["14Hematology Department, Hospital Clinic Barcelona, Barcelona, Spain","Hospital Clinic de Barcelona, Barcelona, Spain"],"raw_orcid":"https://orcid.org/0000-0002-8588-8381","affiliations":[{"raw_affiliation_string":"14Hematology Department, Hospital Clinic Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097"]},{"raw_affiliation_string":"Hospital Clinic de Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057382090","display_name":"David Schr\u00f6der","orcid":"https://orcid.org/0000-0001-9588-0415","observed_orcids":["https://orcid.org/0000-0001-9588-0415"]},"institutions":[{"id":"https://openalex.org/I4210152698","display_name":"Grand Charleroi Hospital","ror":"https://ror.org/05ma41w62","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I4210152698"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"David Schr\u00f6der","raw_affiliation_strings":["15Medical Oncology Department, Grand H\u00f4pital de Charleroi, Charleroi, Belgium","Grand H\u00f4pital de Charleroi, Charleroi, Belgium"],"raw_orcid":"https://orcid.org/0000-0001-9588-0415","affiliations":[{"raw_affiliation_string":"15Medical Oncology Department, Grand H\u00f4pital de Charleroi, Charleroi, Belgium","institution_ids":["https://openalex.org/I4210152698"]},{"raw_affiliation_string":"Grand H\u00f4pital de Charleroi, Charleroi, Belgium","institution_ids":["https://openalex.org/I4210152698"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002237204","display_name":"Rafa\u0142 Stec","orcid":"https://orcid.org/0000-0002-3291-6422","observed_orcids":["https://orcid.org/0000-0002-3291-6422"]},"institutions":[{"id":"https://openalex.org/I268303160","display_name":"Medical University of Warsaw","ror":"https://ror.org/04p2y4s44","country_code":"PL","type":"education","lineage":["https://openalex.org/I268303160"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Rafal Stec","raw_affiliation_strings":["16Department of Oncology, Warsaw Medical University, Warsaw, Poland","17Biokinetica, J\u00f3zef\u00f3w, Poland","Warsaw Medical University, Warsaw, Poland"],"raw_orcid":"https://orcid.org/0000-0002-3291-6422","affiliations":[{"raw_affiliation_string":"16Department of Oncology, Warsaw Medical University, Warsaw, Poland","institution_ids":["https://openalex.org/I268303160"]},{"raw_affiliation_string":"17Biokinetica, J\u00f3zef\u00f3w, Poland","institution_ids":[]},{"raw_affiliation_string":"Warsaw Medical University, Warsaw, Poland","institution_ids":["https://openalex.org/I268303160"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010026747","display_name":"Allison Berger","orcid":"https://orcid.org/0000-0003-1217-2005","observed_orcids":["https://orcid.org/0000-0003-1217-2005"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allison Berger","raw_affiliation_strings":["18Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Takeda Development Center Americas, Cambridge, MA, United States"],"raw_orcid":"https://orcid.org/0000-0003-1217-2005","affiliations":[{"raw_affiliation_string":"18Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":[]},{"raw_affiliation_string":"Takeda Development Center Americas, Cambridge, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101298749","display_name":"Bo Chao","orcid":"https://orcid.org/0009-0001-0627-8033","observed_orcids":["https://orcid.org/0009-0001-0627-8033"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bo Chao","raw_affiliation_strings":["19Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States"],"raw_orcid":"https://orcid.org/0009-0001-0627-8033","affiliations":[{"raw_affiliation_string":"19Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108608033","display_name":"Aleksander Chudnovsky","orcid":"https://orcid.org/0009-0007-4961-5291","observed_orcids":["https://orcid.org/0009-0007-4961-5291"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aleksander Chudnovsky","raw_affiliation_strings":["20Oncology Clinical Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Pfizer (United States), Cambridge, Massachusetts, United States"],"raw_orcid":"https://orcid.org/0009-0007-4961-5291","affiliations":[{"raw_affiliation_string":"20Oncology Clinical Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":[]},{"raw_affiliation_string":"Pfizer (United States), Cambridge, Massachusetts, United States","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011111764","display_name":"John P. Gibbs","orcid":"https://orcid.org/0000-0001-8892-7318","observed_orcids":["https://orcid.org/0000-0001-8892-7318"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John P. Gibbs","raw_affiliation_strings":["21Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States"],"raw_orcid":"https://orcid.org/0000-0001-8892-7318","affiliations":[{"raw_affiliation_string":"21Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083958966","display_name":"Tao Long","orcid":"https://orcid.org/0000-0002-0676-391X","observed_orcids":["https://orcid.org/0000-0002-0676-391X"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tao Long","raw_affiliation_strings":["21Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States"],"raw_orcid":"https://orcid.org/0000-0002-0676-391X","affiliations":[{"raw_affiliation_string":"21Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063721216","display_name":"Dina Stroopinsky","orcid":"https://orcid.org/0009-0006-7359-1560","observed_orcids":["https://orcid.org/0009-0006-7359-1560"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dina Stroopinsky","raw_affiliation_strings":["18Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States"],"raw_orcid":"https://orcid.org/0009-0006-7359-1560","affiliations":[{"raw_affiliation_string":"18Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":[]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Qi Dong","orcid":"https://orcid.org/0009-0008-0291-1840","observed_orcids":["https://orcid.org/0009-0008-0291-1840"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Qi Dong","raw_affiliation_strings":["22Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States"],"raw_orcid":"https://orcid.org/0009-0008-0291-1840","affiliations":[{"raw_affiliation_string":"22Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts","institution_ids":[]},{"raw_affiliation_string":"Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076736008","display_name":"Anthony J. Olszanski","orcid":"https://orcid.org/0000-0001-5276-5898","observed_orcids":["https://orcid.org/0000-0001-5276-5898"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony J. Olszanski","raw_affiliation_strings":["23Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States"],"raw_orcid":"https://orcid.org/0000-0001-5276-5898","affiliations":[{"raw_affiliation_string":"23Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I1289437631"]},{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","institution_ids":["https://openalex.org/I1289437631"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":26,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210140176"],"apc_list":{"value":2550,"currency":"USD","value_usd":2550},"apc_paid":{"value":2550,"currency":"USD","value_usd":2550},"fwci":4.723,"has_fulltext":true,"cited_by_count":13,"citation_normalized_percentile":{"value":0.96032088,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"5","issue":"11","first_page":"2025","last_page":"2038"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5023999810218811,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5023999810218811,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.15549999475479126,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.09470000118017197,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/subasumstat","display_name":"subasumstat","score":0.9959999918937683},{"id":"https://openalex.org/keywords/tak-981","display_name":"TAK-981","score":0.9769999980926514},{"id":"https://openalex.org/keywords/sumoylation-inhibitors","display_name":"SUMOylation inhibitors","score":0.9419999718666077},{"id":"https://openalex.org/keywords/type-i-interferon","display_name":"type I interferon","score":0.7789999842643738},{"id":"https://openalex.org/keywords/innate-and-adaptive-immunity","display_name":"innate and adaptive immunity","score":0.5870000123977661},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7889999747276306},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.984000027179718},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.8069999814033508},{"id":"https://openalex.org/keywords/relapsed-refractory-hematologic-malignancies","display_name":"relapsed/refractory hematologic malignancies","score":0.8399999737739563},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.765999972820282},{"id":"https://openalex.org/keywords/cytokine-production","display_name":"cytokine production","score":0.5239999890327454},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.656000018119812},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.40299999713897705}],"concepts":[{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.6567999720573425},{"id":"https://openalex.org/C171350616","wikidata":"https://www.wikidata.org/wiki/Q61506","display_name":"SUMO protein","level":4,"score":0.6031000018119812},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6018000245094299},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5030999779701233},{"id":"https://openalex.org/C136449434","wikidata":"https://www.wikidata.org/wiki/Q428253","display_name":"Innate immune system","level":3,"score":0.44209998846054077},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.42829999327659607},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4090000092983246},{"id":"https://openalex.org/C116834253","wikidata":"https://www.wikidata.org/wiki/Q2039217","display_name":"Identification (biology)","level":2,"score":0.3425999879837036},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3151000142097473},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.30410000681877136},{"id":"https://openalex.org/C193419808","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired immune system","level":3,"score":0.29409998655319214},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.2897000014781952},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2732999920845032},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.27219998836517334},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.27059999108314514},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.26260000467300415},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.2590000033378601},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.25380000472068787}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D058207","descriptor_name":"Sumoylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D058207","descriptor_name":"Sumoylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D058207","descriptor_name":"Sumoylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D058207","descriptor_name":"Sumoylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D058207","descriptor_name":"Sumoylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D058207","descriptor_name":"Sumoylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1158/2767-9764.crc-25-0243","doi":"https://doi.org/10.1158/2767-9764.crc-25-0243","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-25-0243","pdf_url":"https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-25-0243/3665428/crc-25-0243.pdf","source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},{"id":"pmid:41134690","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41134690","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research communications","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:11435998","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12627933","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:dial.uclouvain.be:boreal:308542","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/2078.1/308542","pdf_url":null,"source":{"id":"https://openalex.org/S4306401902","display_name":"Digital Access to Libraries (Universit\u00e9 catholique de Louvain (UCL), l'Universit\u00e9 de Namur (UNamur) and the Universit\u00e9 Saint-Louis (USL-B))","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I95674353","host_organization_name":"UCLouvain","host_organization_lineage":["https://openalex.org/I95674353"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cancer research communications, Vol. 5, no.11, p. 2025-2038 (2025)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1158/2767-9764.crc-25-0243","doi":"https://doi.org/10.1158/2767-9764.crc-25-0243","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-25-0243","pdf_url":"https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-25-0243/3665428/crc-25-0243.pdf","source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F1462049487","display_name":"Takeda Development Center Americas","ror":null},{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320318946","display_name":"Relay Therapeutics","ror":"https://ror.org/02bkgy413"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4415523640.pdf","grobid_xml":"https://content.openalex.org/works/W4415523640.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W2013108773","https://openalex.org/W2077031094","https://openalex.org/W2112441454","https://openalex.org/W2119147717","https://openalex.org/W2199392899","https://openalex.org/W2905654445","https://openalex.org/W3003760629","https://openalex.org/W3048466782","https://openalex.org/W3092458803","https://openalex.org/W3097610823","https://openalex.org/W3131360915","https://openalex.org/W3200597919","https://openalex.org/W3214477505","https://openalex.org/W4207049733","https://openalex.org/W4214483742","https://openalex.org/W4283377063","https://openalex.org/W4286297044","https://openalex.org/W4365448944","https://openalex.org/W4365511944","https://openalex.org/W4382776828","https://openalex.org/W4388342238","https://openalex.org/W4410533018"],"related_works":[],"abstract_inverted_index":{"PURPOSE:":[0],"Subasumstat":[1,214],"(TAK-981)":[2],"is":[3],"a":[4,28,46,206,216,276],"first-in-class":[5,277],"inhibitor":[6],"of":[7,43,97,119,165,175,222,247,254,289,296],"SUMOylation":[8,161,278],"that":[9],"can":[10],"engage":[11],"innate":[12,176,223,297],"and":[13,40,55,76,83,128,152,160,170,173,177,185,202,209,224,235,256,284,291,294,298],"adaptive":[14,178,225,299],"immune":[15,179,226,300],"responses":[16],"in":[17,49,85,229,249],"tumors":[18,54,234],"by":[19],"enhancing":[20],"type":[21],"I":[22],"IFN":[23,290],"(IFNI)":[24],"production.":[25],"We":[26],"conducted":[27],"phase":[29,112,197,272],"I/II":[30,273],"dose-escalation/-expansion":[31],"study":[32],"(NCT03648372)":[33],"to":[34,243,264],"investigate":[35],"the":[36,138,195,245],"safety,":[37,183],"pharmacokinetics,":[38],"pharmacodynamics,":[39],"preliminary":[41,281],"efficacy":[42],"subasumstat":[44,65,248],"as":[45,137,194],"single":[47],"agent":[48],"patients":[50,63,99,115,204,230,260],"with":[51,220,231],"advanced/metastatic":[52,232],"solid":[53,233],"relapsed/refractory":[56,236],"hematologic":[57,237],"malignancies.":[58,238],"PATIENTS":[59],"AND":[60],"METHODS:":[61],"Eligible":[62],"received":[64],"intravenously":[66],"at":[67],"escalating":[68],"doses":[69],"twice":[70,133,190],"weekly":[71,80,134,191],"(days":[72,81],"1,":[73],"4,":[74],"8,":[75],"11)":[77],"or":[78,91],"once":[79],"1":[82],"8)":[84],"21-day":[86],"cycles":[87],"until":[88],"disease":[89],"progression":[90],"unacceptable":[92],"toxicity.":[93],"RESULTS:":[94],"A":[95],"total":[96],"109":[98],"were":[100,145],"enrolled":[101],"(solid":[102],"tumors:":[103],"n":[104,108],"=":[105,109],"100;":[106],"lymphomas,":[107],"9).":[110],"In":[111,270],"I,":[113],"four":[114],"reported":[116],"dose-limiting":[117],"toxicities":[118],"grade":[120],"3":[121],"alanine":[122],"transaminase/aspartate":[123],"transaminase":[124],"elevation,":[125],"pneumonitis,":[126],"stomatitis,":[127],"cognitive":[129],"disorder;":[130],"120":[131],"mg":[132,189],"was":[135,192],"determined":[136],"MTD.":[139],"The":[140],"most":[141],"common":[142],"adverse":[143],"events":[144],"fatigue":[146],"(47%),":[147],"nausea":[148],"(41%),":[149],"diarrhea":[150],"(36%),":[151],"pyrexia":[153],"(36%).":[154],"Pharmacodynamic":[155],"analyses":[156],"demonstrated":[157,285],"target":[158,286],"engagement":[159,228],"pathway":[162],"inhibition,":[163],"induction":[164],"an":[166],"IFNI-regulated":[167],"gene":[168],"signature":[169],"cytokine":[171],"production,":[172],"activation":[174,295],"cells.":[180,301],"Based":[181],"on":[182],"pharmacokinetic,":[184],"pharmacodynamic":[186],"findings,":[187],"90":[188],"proposed":[193],"recommended":[196],"II":[198],"dosage.":[199],"Overall,":[200],"three":[201],"26":[203],"achieved":[205],"partial":[207],"response":[208,227],"stable":[210],"disease,":[211],"respectively.":[212],"CONCLUSIONS:":[213],"had":[215,280],"manageable":[217],"safety":[218],"profile,":[219],"evidence":[221],"Further":[239],"studies":[240],"are":[241],"needed":[242],"determine":[244],"role":[246],"cancer":[250],"treatment.":[251],"SIGNIFICANCE:":[252],"Identification":[253],"novel":[255],"effective":[257],"therapies":[258],"for":[259],"who":[261],"become":[262],"refractory":[263],"standard":[265],"anticancer":[266],"treatments":[267],"remains":[268],"paramount.":[269],"this":[271],"study,":[274],"subasumstat,":[275],"inhibitor,":[279],"clinical":[282],"activity":[283],"engagement,":[287],"upregulation":[288],"plasma":[292],"cytokines,":[293]},"counts_by_year":[{"year":2026,"cited_by_count":13}],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2025-10-24T00:00:00"}